Treg therapeutic designed to preferentially traffic towards its ligand CXCL12 over expressed in the bone marrow and spleen in myelofibrosis. -- CK0804 engages with antigen presenting cells within ...

The study shows that this drug pair works far better together than either agent alone, offering a realistic and potentially fast path toward a new ...

Researchers at Kumamoto University have uncovered a previously unknown molecular mechanism by which human T-cell leukemia ...

Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional ...